 Kendra Young
Concepts (318)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 28 | 2025 | 1036 | 2.760 |
Why?
| | Lupus Erythematosus, Systemic | 10 | 2022 | 242 | 2.510 |
Why?
| | Genetic Predisposition to Disease | 17 | 2025 | 2412 | 1.280 |
Why?
| | Smoking | 14 | 2024 | 1620 | 1.090 |
Why?
| | Tobacco Use Disorder | 4 | 2022 | 251 | 1.030 |
Why?
| | Genome-Wide Association Study | 18 | 2025 | 1428 | 0.930 |
Why?
| | Receptors, Complement 3d | 10 | 2010 | 141 | 0.920 |
Why?
| | Mexican Americans | 2 | 2019 | 120 | 0.910 |
Why?
| | Autoantibodies | 8 | 2022 | 1496 | 0.880 |
Why?
| | Smokers | 9 | 2023 | 145 | 0.870 |
Why?
| | Bronchiectasis | 5 | 2023 | 111 | 0.860 |
Why?
| | Vitamin D | 5 | 2022 | 397 | 0.850 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2023 | 279 | 0.790 |
Why?
| | Coronary Artery Disease | 5 | 2025 | 698 | 0.780 |
Why?
| | Polymorphism, Single Nucleotide | 14 | 2025 | 2184 | 0.770 |
Why?
| | Herpesvirus 4, Human | 4 | 2019 | 167 | 0.740 |
Why?
| | Vitamin D Deficiency | 2 | 2016 | 186 | 0.730 |
Why?
| | Pulmonary Emphysema | 6 | 2025 | 288 | 0.720 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2023 | 2518 | 0.700 |
Why?
| | Spirometry | 11 | 2025 | 281 | 0.660 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 85 | 0.650 |
Why?
| | Alanine Transaminase | 2 | 2020 | 157 | 0.640 |
Why?
| | Tomography, X-Ray Computed | 13 | 2025 | 2666 | 0.620 |
Why?
| | Family | 2 | 2014 | 664 | 0.620 |
Why?
| | Aspartate Aminotransferases | 1 | 2019 | 90 | 0.610 |
Why?
| | Lipase | 1 | 2019 | 69 | 0.610 |
Why?
| | Inflammation Mediators | 2 | 2019 | 513 | 0.600 |
Why?
| | Virus Attachment | 2 | 2008 | 16 | 0.580 |
Why?
| | Arthritis, Rheumatoid | 5 | 2024 | 1167 | 0.580 |
Why?
| | Cholesterol, HDL | 1 | 2018 | 203 | 0.570 |
Why?
| | Smoking Cessation | 1 | 2022 | 436 | 0.560 |
Why?
| | Forced Expiratory Volume | 13 | 2025 | 531 | 0.560 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2016 | 15 | 0.510 |
Why?
| | Triglycerides | 1 | 2018 | 524 | 0.500 |
Why?
| | Membrane Proteins | 2 | 2020 | 1163 | 0.500 |
Why?
| | Middle Aged | 35 | 2025 | 33225 | 0.500 |
Why?
| | Adiposity | 2 | 2012 | 518 | 0.480 |
Why?
| | Metabolic Syndrome | 1 | 2018 | 354 | 0.460 |
Why?
| | Humans | 77 | 2025 | 136750 | 0.460 |
Why?
| | Genetic Variation | 6 | 2025 | 985 | 0.440 |
Why?
| | Insulin-Secreting Cells | 1 | 2018 | 372 | 0.430 |
Why?
| | Atherosclerosis | 3 | 2023 | 415 | 0.420 |
Why?
| | Insulin Resistance | 2 | 2018 | 1203 | 0.400 |
Why?
| | Male | 39 | 2025 | 67305 | 0.400 |
Why?
| | Female | 41 | 2025 | 72785 | 0.390 |
Why?
| | Viral Matrix Proteins | 4 | 2008 | 30 | 0.390 |
Why?
| | Joints | 1 | 2013 | 105 | 0.390 |
Why?
| | Risk Factors | 20 | 2025 | 10330 | 0.370 |
Why?
| | Sleep | 1 | 2018 | 753 | 0.370 |
Why?
| | Complement C3d | 7 | 2010 | 67 | 0.360 |
Why?
| | Hypertension | 1 | 2020 | 1285 | 0.360 |
Why?
| | Emphysema | 2 | 2023 | 106 | 0.350 |
Why?
| | Genetic Loci | 4 | 2022 | 288 | 0.330 |
Why?
| | Follow-Up Studies | 9 | 2025 | 5105 | 0.330 |
Why?
| | Disease Progression | 6 | 2025 | 2751 | 0.330 |
Why?
| | Autoimmunity | 3 | 2022 | 908 | 0.330 |
Why?
| | Adult | 18 | 2024 | 37626 | 0.300 |
Why?
| | Calcinosis | 1 | 2010 | 235 | 0.300 |
Why?
| | Diabetic Angiopathies | 1 | 2010 | 259 | 0.300 |
Why?
| | Prospective Studies | 11 | 2024 | 7572 | 0.280 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2105 | 0.280 |
Why?
| | Genotype | 7 | 2024 | 1914 | 0.270 |
Why?
| | Aged | 19 | 2025 | 23800 | 0.270 |
Why?
| | Viral Envelope Proteins | 1 | 2007 | 84 | 0.270 |
Why?
| | HLA-DR4 Antigen | 1 | 2007 | 78 | 0.260 |
Why?
| | Lung | 10 | 2025 | 4061 | 0.260 |
Why?
| | Linkage Disequilibrium | 2 | 2024 | 268 | 0.260 |
Why?
| | Phenotype | 9 | 2025 | 3189 | 0.250 |
Why?
| | Longitudinal Studies | 7 | 2025 | 2829 | 0.250 |
Why?
| | Rheumatoid Factor | 1 | 2007 | 175 | 0.250 |
Why?
| | Vital Capacity | 5 | 2025 | 309 | 0.240 |
Why?
| | Glycoproteins | 1 | 2007 | 342 | 0.240 |
Why?
| | Tobacco Use | 2 | 2023 | 64 | 0.240 |
Why?
| | Genomic Structural Variation | 1 | 2025 | 12 | 0.230 |
Why?
| | Receptors, CCR2 | 1 | 2025 | 40 | 0.230 |
Why?
| | Genetic Markers | 2 | 2019 | 344 | 0.230 |
Why?
| | Population Surveillance | 2 | 2021 | 473 | 0.230 |
Why?
| | Case-Control Studies | 7 | 2025 | 3540 | 0.230 |
Why?
| | Multifactorial Inheritance | 2 | 2023 | 174 | 0.230 |
Why?
| | Acyltransferases | 2 | 2023 | 56 | 0.220 |
Why?
| | Vitamin D-Binding Protein | 2 | 2016 | 15 | 0.220 |
Why?
| | Alcohol Drinking | 2 | 2022 | 820 | 0.220 |
Why?
| | Cohort Studies | 7 | 2023 | 5703 | 0.210 |
Why?
| | Receptors, Calcitriol | 2 | 2016 | 55 | 0.210 |
Why?
| | Liver | 3 | 2023 | 1940 | 0.210 |
Why?
| | Plaque, Atherosclerotic | 1 | 2023 | 57 | 0.200 |
Why?
| | Drug Repositioning | 1 | 2023 | 35 | 0.200 |
Why?
| | Tomography, Emission-Computed | 1 | 2022 | 66 | 0.200 |
Why?
| | Peptides, Cyclic | 2 | 2015 | 259 | 0.200 |
Why?
| | Autoimmune Diseases | 1 | 2007 | 460 | 0.200 |
Why?
| | Artificial Intelligence | 2 | 2023 | 275 | 0.200 |
Why?
| | Risk Assessment | 5 | 2019 | 3432 | 0.190 |
Why?
| | Population Health | 1 | 2023 | 47 | 0.190 |
Why?
| | Hyperlipidemias | 1 | 2023 | 120 | 0.190 |
Why?
| | Internationality | 1 | 2022 | 154 | 0.190 |
Why?
| | Airway Obstruction | 1 | 2024 | 162 | 0.190 |
Why?
| | Liver Cirrhosis | 2 | 2023 | 316 | 0.190 |
Why?
| | Symptom Flare Up | 1 | 2021 | 40 | 0.180 |
Why?
| | Models, Genetic | 1 | 2024 | 599 | 0.180 |
Why?
| | Pulmonary Artery | 3 | 2024 | 1085 | 0.170 |
Why?
| | Proteome | 1 | 2025 | 472 | 0.170 |
Why?
| | Muscular Atrophy | 1 | 2021 | 83 | 0.170 |
Why?
| | Atrial Fibrillation | 1 | 2025 | 387 | 0.170 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2010 | 374 | 0.170 |
Why?
| | Amino Acid Substitution | 4 | 2010 | 306 | 0.170 |
Why?
| | Respiratory Function Tests | 2 | 2019 | 594 | 0.160 |
Why?
| | Linear Models | 2 | 2019 | 845 | 0.160 |
Why?
| | China | 1 | 2020 | 216 | 0.160 |
Why?
| | Gene Frequency | 4 | 2024 | 520 | 0.160 |
Why?
| | Quantitative Trait, Heritable | 1 | 2020 | 125 | 0.160 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 6 | 0.160 |
Why?
| | Molecular Epidemiology | 1 | 2019 | 67 | 0.160 |
Why?
| | Alleles | 3 | 2019 | 890 | 0.160 |
Why?
| | Transcriptome | 2 | 2023 | 969 | 0.160 |
Why?
| | Prevalence | 6 | 2023 | 2708 | 0.160 |
Why?
| | Blood Pressure Determination | 1 | 2020 | 156 | 0.160 |
Why?
| | Prognosis | 4 | 2024 | 4012 | 0.160 |
Why?
| | gamma-Glutamyltransferase | 1 | 2019 | 43 | 0.160 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2020 | 3710 | 0.160 |
Why?
| | Nuclear Family | 1 | 2019 | 54 | 0.150 |
Why?
| | Biomarkers | 2 | 2025 | 4145 | 0.150 |
Why?
| | Whole Genome Sequencing | 3 | 2025 | 153 | 0.150 |
Why?
| | Binding Sites | 5 | 2010 | 1301 | 0.150 |
Why?
| | Antigens, Viral | 1 | 2019 | 181 | 0.150 |
Why?
| | Proteomics | 1 | 2025 | 1109 | 0.150 |
Why?
| | Hepatitis C | 2 | 2011 | 266 | 0.150 |
Why?
| | Heart Ventricles | 2 | 2020 | 785 | 0.140 |
Why?
| | Dyspnea | 3 | 2025 | 252 | 0.140 |
Why?
| | Herpesviridae Infections | 1 | 2019 | 149 | 0.140 |
Why?
| | Protein Binding | 7 | 2010 | 2216 | 0.140 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2017 | 31 | 0.140 |
Why?
| | Vascular Remodeling | 1 | 2019 | 190 | 0.140 |
Why?
| | Blood Pressure | 2 | 2023 | 1774 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2819 | 0.130 |
Why?
| | Coronary Vessels | 1 | 2018 | 244 | 0.130 |
Why?
| | Lung Diseases | 1 | 2023 | 768 | 0.130 |
Why?
| | Protein Structure, Tertiary | 3 | 2008 | 860 | 0.130 |
Why?
| | United States | 5 | 2020 | 14682 | 0.130 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2016 | 17 | 0.130 |
Why?
| | Crystallography, X-Ray | 6 | 2010 | 476 | 0.130 |
Why?
| | Complement C3b | 3 | 2007 | 34 | 0.130 |
Why?
| | Mutation, Missense | 2 | 2008 | 337 | 0.120 |
Why?
| | Fatigue | 1 | 2018 | 326 | 0.120 |
Why?
| | Lipids | 1 | 2020 | 665 | 0.120 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 83 | 0.120 |
Why?
| | Body Mass Index | 3 | 2021 | 2373 | 0.120 |
Why?
| | Antibodies, Viral | 1 | 2019 | 623 | 0.120 |
Why?
| | Machine Learning | 1 | 2019 | 488 | 0.110 |
Why?
| | Abdominal Fat | 2 | 2017 | 41 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 139 | 0.110 |
Why?
| | Antibodies, Antinuclear | 1 | 2014 | 71 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2019 | 1507 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 851 | 0.100 |
Why?
| | Europe | 3 | 2022 | 413 | 0.100 |
Why?
| | Quality of Life | 2 | 2025 | 2876 | 0.100 |
Why?
| | Fluorescent Antibody Technique | 1 | 2014 | 388 | 0.100 |
Why?
| | Hyperglycemia | 1 | 2016 | 347 | 0.100 |
Why?
| | Calcium | 1 | 2018 | 1197 | 0.100 |
Why?
| | Family Health | 1 | 2013 | 196 | 0.100 |
Why?
| | Sample Size | 2 | 2022 | 125 | 0.100 |
Why?
| | Recombinant Proteins | 5 | 2007 | 1350 | 0.100 |
Why?
| | Models, Molecular | 6 | 2008 | 1569 | 0.100 |
Why?
| | Peptide Fragments | 3 | 2007 | 705 | 0.090 |
Why?
| | Mutant Proteins | 2 | 2010 | 101 | 0.090 |
Why?
| | Cross-Sectional Studies | 4 | 2024 | 5419 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2019 | 1260 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 626 | 0.090 |
Why?
| | Texas | 1 | 2012 | 241 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1904 | 0.090 |
Why?
| | Registries | 1 | 2019 | 2014 | 0.090 |
Why?
| | Protein Interaction Mapping | 2 | 2008 | 109 | 0.090 |
Why?
| | Antibodies, Monoclonal | 4 | 2007 | 1430 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 530 | 0.090 |
Why?
| | K562 Cells | 2 | 2007 | 89 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2021 | 0.080 |
Why?
| | Epidemics | 1 | 2011 | 89 | 0.080 |
Why?
| | Life Style | 1 | 2012 | 487 | 0.080 |
Why?
| | Depression | 1 | 2018 | 1397 | 0.080 |
Why?
| | Intra-Abdominal Fat | 1 | 2009 | 91 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2021 | 15499 | 0.070 |
Why?
| | Sex Factors | 2 | 2020 | 2064 | 0.070 |
Why?
| | Regression Analysis | 2 | 2022 | 1022 | 0.070 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2008 | 150 | 0.070 |
Why?
| | Point Mutation | 1 | 2008 | 235 | 0.070 |
Why?
| | Exercise Tolerance | 2 | 2020 | 279 | 0.070 |
Why?
| | Meta-Analysis as Topic | 2 | 2020 | 186 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 659 | 0.070 |
Why?
| | Bottle Feeding | 1 | 2007 | 21 | 0.070 |
Why?
| | Bronchodilator Agents | 2 | 2021 | 247 | 0.070 |
Why?
| | Histocompatibility Testing | 1 | 2007 | 126 | 0.070 |
Why?
| | Insulin | 1 | 2017 | 2406 | 0.060 |
Why?
| | Hospitalization | 1 | 2016 | 2181 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5739 | 0.060 |
Why?
| | Health Behavior | 1 | 2012 | 756 | 0.060 |
Why?
| | Bronchitis, Chronic | 1 | 2025 | 25 | 0.060 |
Why?
| | Interferon-alpha | 1 | 2006 | 198 | 0.060 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2025 | 52 | 0.060 |
Why?
| | Chemokine CCL2 | 1 | 2025 | 115 | 0.060 |
Why?
| | Tobacco Smoke Pollution | 1 | 2007 | 261 | 0.050 |
Why?
| | Phospholipases | 1 | 2023 | 14 | 0.050 |
Why?
| | Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2023 | 26 | 0.050 |
Why?
| | United Kingdom | 1 | 2024 | 310 | 0.050 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2023 | 90 | 0.050 |
Why?
| | Multimorbidity | 1 | 2023 | 47 | 0.050 |
Why?
| | Pandemics | 1 | 2011 | 1615 | 0.050 |
Why?
| | Computer Simulation | 2 | 2024 | 973 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2024 | 266 | 0.050 |
Why?
| | Monocytes | 1 | 2025 | 563 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2007 | 846 | 0.050 |
Why?
| | Pectoralis Muscles | 1 | 2021 | 18 | 0.050 |
Why?
| | Biology | 1 | 2023 | 87 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2019 | 7593 | 0.050 |
Why?
| | Reference Values | 1 | 2023 | 816 | 0.050 |
Why?
| | Epitope Mapping | 1 | 2001 | 62 | 0.050 |
Why?
| | Colorado | 1 | 2012 | 4512 | 0.050 |
Why?
| | Logistic Models | 1 | 2007 | 2067 | 0.050 |
Why?
| | Bronchi | 1 | 2022 | 260 | 0.040 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 37 | 0.040 |
Why?
| | Ligands | 4 | 2006 | 661 | 0.040 |
Why?
| | Vitamins | 1 | 2022 | 185 | 0.040 |
Why?
| | Inheritance Patterns | 1 | 2020 | 45 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 3406 | 0.040 |
Why?
| | Molecular Sequence Annotation | 1 | 2020 | 97 | 0.040 |
Why?
| | Myocytes, Cardiac | 1 | 2025 | 523 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 455 | 0.040 |
Why?
| | Interleukin-10 | 1 | 2022 | 302 | 0.040 |
Why?
| | Models, Statistical | 1 | 2024 | 668 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 9 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 12 | 0.040 |
Why?
| | Drug Discovery | 1 | 2020 | 141 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2022 | 480 | 0.040 |
Why?
| | Hepacivirus | 2 | 2011 | 260 | 0.040 |
Why?
| | Age Factors | 1 | 2007 | 3286 | 0.040 |
Why?
| | Walk Test | 1 | 2019 | 76 | 0.040 |
Why?
| | Surface Plasmon Resonance | 3 | 2006 | 87 | 0.040 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 48 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2021 | 683 | 0.040 |
Why?
| | Binding, Competitive | 3 | 2006 | 202 | 0.040 |
Why?
| | Organ Size | 1 | 2019 | 477 | 0.040 |
Why?
| | Organ Specificity | 1 | 2019 | 304 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 788 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2019 | 497 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1062 | 0.040 |
Why?
| | Self Report | 1 | 2022 | 822 | 0.030 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 283 | 0.030 |
Why?
| | Body Composition | 1 | 2021 | 678 | 0.030 |
Why?
| | Tobacco Products | 1 | 2019 | 136 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 556 | 0.030 |
Why?
| | Environment | 1 | 2019 | 357 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 328 | 0.030 |
Why?
| | Chronic Disease | 1 | 2023 | 1786 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 361 | 0.030 |
Why?
| | Incidence | 2 | 2015 | 2797 | 0.030 |
Why?
| | Cause of Death | 1 | 2018 | 429 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 888 | 0.030 |
Why?
| | Risk | 1 | 2019 | 908 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2017 | 364 | 0.030 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2015 | 30 | 0.030 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 2015 | 55 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2017 | 380 | 0.030 |
Why?
| | Amino Acid Sequence | 3 | 2006 | 2138 | 0.030 |
Why?
| | Receptors, IgE | 2 | 2006 | 45 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2006 | 2894 | 0.030 |
Why?
| | Repetitive Sequences, Amino Acid | 2 | 2005 | 17 | 0.030 |
Why?
| | Mutagenesis | 2 | 2006 | 179 | 0.030 |
Why?
| | Genome, Human | 1 | 2015 | 423 | 0.030 |
Why?
| | Solutions | 2 | 2005 | 167 | 0.020 |
Why?
| | Child, Preschool | 1 | 2007 | 10997 | 0.020 |
Why?
| | Egypt | 1 | 2011 | 11 | 0.020 |
Why?
| | Israel | 1 | 2011 | 56 | 0.020 |
Why?
| | Asia | 1 | 2011 | 70 | 0.020 |
Why?
| | Consensus Sequence | 2 | 2001 | 73 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2835 | 0.020 |
Why?
| | Protein Conformation | 2 | 2006 | 933 | 0.020 |
Why?
| | Time Factors | 2 | 2011 | 6808 | 0.020 |
Why?
| | Australia | 1 | 2011 | 313 | 0.020 |
Why?
| | Canada | 1 | 2011 | 421 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2010 | 211 | 0.020 |
Why?
| | Infant | 1 | 2021 | 9395 | 0.020 |
Why?
| | Spodoptera | 1 | 2006 | 40 | 0.020 |
Why?
| | Child | 1 | 2007 | 21816 | 0.020 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2006 | 13 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2006 | 82 | 0.020 |
Why?
| | Polysaccharides | 1 | 2006 | 79 | 0.020 |
Why?
| | Glycosylation | 1 | 2006 | 151 | 0.020 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2006 | 27 | 0.020 |
Why?
| | GTP-Binding Proteins | 1 | 2006 | 161 | 0.020 |
Why?
| | Sodium Chloride | 1 | 2006 | 142 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 560 | 0.010 |
Why?
| | Protein Structure, Quaternary | 1 | 2005 | 125 | 0.010 |
Why?
| | Static Electricity | 1 | 2005 | 118 | 0.010 |
Why?
| | Dimerization | 1 | 2005 | 198 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2006 | 500 | 0.010 |
Why?
| | Multiprotein Complexes | 1 | 2005 | 163 | 0.010 |
Why?
| | Animals | 4 | 2010 | 36836 | 0.010 |
Why?
| | Neutrons | 1 | 2002 | 10 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1089 | 0.010 |
Why?
| | Scattering, Radiation | 1 | 2002 | 101 | 0.010 |
Why?
| | Antigen-Antibody Complex | 1 | 2001 | 90 | 0.010 |
Why?
| | Protein Sorting Signals | 1 | 2001 | 20 | 0.010 |
Why?
| | Pichia | 1 | 2001 | 20 | 0.010 |
Why?
| | Ultracentrifugation | 1 | 2001 | 52 | 0.010 |
Why?
| | Hydrogen Bonding | 1 | 2001 | 163 | 0.010 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2001 | 144 | 0.010 |
Why?
| | Cell Line | 1 | 2006 | 2838 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2001 | 342 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 2001 | 374 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2001 | 534 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2001 | 570 | 0.010 |
Why?
| | Protein Folding | 1 | 2001 | 280 | 0.010 |
Why?
| | Complement Activation | 1 | 2002 | 410 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2006 | 4192 | 0.010 |
Why?
| | HIV-1 | 1 | 2001 | 862 | 0.010 |
Why?
| | Models, Biological | 1 | 2002 | 1773 | 0.010 |
Why?
| | Mice | 2 | 2002 | 17758 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2001 | 3009 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2001 | 1993 | 0.010 |
Why?
|
|
Young's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|